Whole genome sequencing of candida glabrata for detection of markers of antifungal drug resistance

Chayanika Biswas*, Sharon C.A. Chen, Catriona Halliday, Elena Martinez, Rebecca J. Rockett, Qinning Wang, Verlaine J. Timms, Rajat Dhakal, Rosemarie Sadsad, Karina J. Kennedy, Geoffrey Playford, Deborah J. Marriott, Monica A. Slavin, Tania C. Sorrell, Vitali Sintchenko

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    20 Citations (Scopus)

    Abstract

    Candida glabrata can rapidly acquire mutations that result in drug resistance, especially to azoles and echinocandins. Identification of genetic mutations is essential, as resistance detected in vitro can often be correlated with clinical failure. We examined the feasibility of using whole genome sequencing (WGS) for genome-wide analysis of antifungal drug resistance in C. glabrata. The aim was torecognize enablers and barriers in the implementation WGS and measure its effectiveness. This paper outlines the key quality control checkpoints and essential components of WGS methodology to investigate genetic markers associated with reduced susceptibility to antifungal agents. It also estimates the accuracy of data analysis and turn-around-time of testing. Phenotypic susceptibility of 12 clinical, and one ATCC strain of C. glabrata was determined through antifungal susceptibility testing. These included three isolate pairs, from three patients, that developed rise in drug minimum inhibitory concentrations. In two pairs, the second isolate of each pair developed resistance to echinocandins. The second isolate of the third pair developed resistance to 5-flucytosine. The remaining comprised of susceptible and azole resistant isolates. Single nucleotide polymorphisms (SNPs) in genes linked to echinocandin, azole and 5-flucytosine resistance were confirmed in resistant isolates through WGS using the next generation sequencing. Non-synonymous SNPs in antifungal resistance genes such as FKS1, FKS2, CgPDR1, CgCDR1 and FCY2 were identified. Overall, an average of 98% of the WGS reads of C. glabrata isolates mapped to the reference genome with about 75-fold read depth coverage. The turnaround time and cost were comparable to Sanger sequencing. In conclusion, WGS of C. glabrata was feasible in revealing clinically significant gene mutations involved in resistance to different antifungal drug classes without the need for multiple PCR/DNA sequencing reactions. This represents a positive step towards establishing WGS capability in the clinical laboratory for simultaneous detection of antifungal resistance conferring substitutions.

    Original languageEnglish
    Article numbere56714
    JournalJournal of Visualized Experiments
    Volume2017
    Issue number130
    DOIs
    Publication statusPublished - 9 Dec 2017

    Fingerprint

    Dive into the research topics of 'Whole genome sequencing of candida glabrata for detection of markers of antifungal drug resistance'. Together they form a unique fingerprint.

    Cite this